Short answer
ImmunityBio, Inc. (IBRX) filed an 8-K current report with the SEC on October 14, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). FDA expanded ANKTIVA plus BCG approval to BCG-unresponsive NMIBC with papillary-only tumors.
ImmunityBio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA expanded ANKTIVA plus BCG approval to BCG-unresponsive NMIBC with papillary-only tumors
- Broader eligible patient population, supporting potential commercial uptake of ANKTIVA
- Press release dated October 14, 2026, contains the full announcement details
Item EX-99.1 · Exhibit EX-99.1
- FDA expanded ANKTIVA plus BCG approval to all BCG-unresponsive NMIBC, including papillary-only tumors
- Papillary disease represents approximately 85% of the NMIBC patient population, materially broadening ANKTIVA’s addressable market
- First FDA-approved therapy covering both CIS and papillary-only BCG-unresponsive NMIBC, strengthening competitive positioning
- QUILT-3.032 Cohort A: 62% complete response among 77 patients, with 58% maintaining response at least 12 months
- Commercial upside depends on physician adoption, reimbursement, supply capacity, and safe use given cystectomy-delay warning
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ImmunityBio, Inc. 8-K filings
Get the next IBRX 8-K as it lands
Follow IBRX for push alerts, or ask the research agent what this filing means.